Gallium Nitrate
drugOn this page
Also known as Gallium nitrate (anhydrous)Gallium nitrate anhydrousGallium nitrate nonahydrateGaniteNitric acidgallium saltNSC-15200
Summary
Gallium Nitrate (CHEMBL1200983) is an approved small molecule; indicated across 7 conditions including lymphoma and non-hodgkin lymphoma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 7 conditions
- Clinical trials: 5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200983 |
| Name | Gallium Nitrate |
| Type | Small molecule |
| Max phase | 4 |
Also known as: Gallium nitrate, Gallium nitrate (anhydrous), Gallium nitrate anhydrous, Gallium nitrate nonahydrate, Ganite, Nitric acid, gallium salt, NSC-15200, GALLIUM NITRATE, Gallium Nitrate
Parent form; salt/anhydrous children: CHEMBL1697699
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| lymphoma | 2 | MONDO:0005062 | EFO:0000574 |
| non-Hodgkin lymphoma | 2 | MONDO:0018908 | EFO:0005952 |
| cystic fibrosis | 2 | MONDO:0009061 | MONDO:0009061 |
| neuroblastoma | 1 | MONDO:0005072 | EFO:0000621 |
| sarcoma | 1 | MONDO:0005089 | EFO:0000691 |
| mycobacterial infectious disease | 1 | MONDO:0020590 | EFO:0009429 |
| central nervous system neoplasm | 1 | MONDO:0006130 | EFO:1000158 |
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 3 |
| PHASE1 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00002578 | PHASE2 | COMPLETED | Gallium Nitrate in Treating Patients With AIDS-Related Non-Hodgkin’s Lymphoma |
| NCT00054808 | PHASE2 | COMPLETED | Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin’s Lymphoma |
| NCT02354859 | PHASE2 | COMPLETED | A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study) |
| NCT04294043 | PHASE1 | RECRUITING | IV Gallium Study for Patients With Cystic Fibrosis Who Have NTM (ABATE Study) |
| NCT00002543 | PHASE1 | COMPLETED | Gallium Nitrate in Treating Children With Brain Tumor, Neuroblastoma, Rhabdomyosarcoma, Non-Hodgkin’s Lymphoma, or Refractory Solid Tumors |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.